FR2874612A1 - Epitotes t cd4+ du vih restreints a hla-dp4 et leurs applications - Google Patents

Epitotes t cd4+ du vih restreints a hla-dp4 et leurs applications

Info

Publication number
FR2874612A1
FR2874612A1 FR0409140A FR0409140A FR2874612A1 FR 2874612 A1 FR2874612 A1 FR 2874612A1 FR 0409140 A FR0409140 A FR 0409140A FR 0409140 A FR0409140 A FR 0409140A FR 2874612 A1 FR2874612 A1 FR 2874612A1
Authority
FR
France
Prior art keywords
hla
totes
restricted hiv
hiv
restricted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
FR0409140A
Other languages
English (en)
Inventor
William Cohen
Moratille Sandra Pouvelle
Gaetan Munier
Bernard Maillere
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Commissariat a lEnergie Atomique et aux Energies Alternatives CEA
Original Assignee
Commissariat a lEnergie Atomique CEA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Commissariat a lEnergie Atomique CEA filed Critical Commissariat a lEnergie Atomique CEA
Priority to FR0409140A priority Critical patent/FR2874612A1/fr
Priority to PCT/FR2005/002152 priority patent/WO2006027468A2/fr
Publication of FR2874612A1 publication Critical patent/FR2874612A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente Invention est relative à des peptides antigéniques du virus de l'immunodéficience humaine (VIH) comprenant au moins un épitope T CD4+ qui est restreint à une molécule HLA-DP4, et à leurs applications vaccinales et diagnostiques.
FR0409140A 2004-08-27 2004-08-27 Epitotes t cd4+ du vih restreints a hla-dp4 et leurs applications Withdrawn FR2874612A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
FR0409140A FR2874612A1 (fr) 2004-08-27 2004-08-27 Epitotes t cd4+ du vih restreints a hla-dp4 et leurs applications
PCT/FR2005/002152 WO2006027468A2 (fr) 2004-08-27 2005-08-26 Epitopes t cd4+ du vih restreints a hla-dp4 et leurs applications

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0409140A FR2874612A1 (fr) 2004-08-27 2004-08-27 Epitotes t cd4+ du vih restreints a hla-dp4 et leurs applications

Publications (1)

Publication Number Publication Date
FR2874612A1 true FR2874612A1 (fr) 2006-03-03

Family

ID=34948781

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0409140A Withdrawn FR2874612A1 (fr) 2004-08-27 2004-08-27 Epitotes t cd4+ du vih restreints a hla-dp4 et leurs applications

Country Status (2)

Country Link
FR (1) FR2874612A1 (fr)
WO (1) WO2006027468A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2830940B1 (fr) 2001-10-17 2007-06-15 Commissariat Energie Atomique Procede de selection de ligands d'hla-dp4 et ses applications
WO2007039458A2 (fr) * 2005-09-21 2007-04-12 Cytos Biotechnology Ag Conjugues peptidiques du vih et leurs utilisations
EP2866820A1 (fr) * 2012-06-27 2015-05-06 Yeda Research and Development Co. Ltd. Peptides issus de gp41 du vih pour le traitement de pathologies à médiation par les lymphocytes t

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998032456A1 (fr) * 1997-01-23 1998-07-30 Epimmune, Inc. Identification d'epitopes a restriction dr largement reactifs
WO2001024810A1 (fr) * 1999-10-05 2001-04-12 Epimmune Inc. Induction de reponses immunitaires cellulaires au virus de l'immunodeficience humaine de type 1 a l'aide de compositions de peptides et d'acides nucleiques
US20040001851A1 (en) * 2001-11-07 2004-01-01 Haynes Barton F. Polyvalent immunogen

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0330359A3 (fr) * 1988-02-25 1991-06-05 Bio-Rad Laboratories, Inc. Composition utile pour le diagnostic et le traitement de l'infection par le HIV-I
EP0339504A3 (fr) * 1988-04-26 1990-09-12 The Du Pont Merck Pharmaceutical Company Virus d'immunodéficience humaine (HIV) peptide env-codé capable de provoquer les anticorps inhibiteurs du HIV dans les mammifères
US5696238A (en) * 1991-08-20 1997-12-09 Chiron Corporation Purified GP120 composition retaining natural conformation
DE69231705T2 (de) * 1992-06-04 2001-10-18 Univ Osaka Res Found Gag-Env Fusion-Antigen aus HIV
BRPI0411127A (pt) * 2003-06-10 2006-05-23 Univ Melbourne composição de matéria para modulação de resposta imuno num sujeito a um antìgeno alvo e respectivos método de modulação, processo de produção de células de apresentação de antìgeno e método de tratamento e/ou profilaxia de doença ou condição associada à presença de antìgeno alvo de interesse

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998032456A1 (fr) * 1997-01-23 1998-07-30 Epimmune, Inc. Identification d'epitopes a restriction dr largement reactifs
WO2001024810A1 (fr) * 1999-10-05 2001-04-12 Epimmune Inc. Induction de reponses immunitaires cellulaires au virus de l'immunodeficience humaine de type 1 a l'aide de compositions de peptides et d'acides nucleiques
US20040001851A1 (en) * 2001-11-07 2004-01-01 Haynes Barton F. Polyvalent immunogen

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
NAKAMURA Y ET AL: "A chain section containing epitopes for cytotoxic T, B and helper T cells within a highly conserved region found in the human immunodeficiency virus type 1 Gag protein", VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, vol. 15, no. 5, 5 April 1997 (1997-04-05), pages 489 - 496, XP004059887, ISSN: 0264-410X *
NISHINO Y ET AL: "IN VIVO INDUCTION OF HUMAN IMMUNODEFICIENCY VIRUS TYPE 1-SPECIFIC CYTOTOXIC T LYMPHOCYTES AND DELAYED-TYPE HYPERSENSITIVITY BY A 23-AMINO ACID PEPTIDE FROM THE HIGHLY CONSERVED REGION IN MAJOR CORE PROTEIN P24", VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, vol. 12, no. 6, May 1994 (1994-05-01), pages 485 - 491, XP000882395, ISSN: 0264-410X *
PANCRÉ V ET AL.: "Novel promiscuous HLA-DQ HIV Nef peptide that induces IFN-gamma-producing memory CD4+ T cells", CLINICAL AND EXPERIMENTAL IMMUNOLOGY, vol. 129, 2002, pages 429 - 437, XP002321844 *
SONG YUB SHIN ET AL: "CHARACTERIZATION OF KI-24, A NOVEL MURINE MONOCLONAL ANTIBODY WITH SPECIFIC REACTIVITY FOR THE HUMAN IMMUNODEFICIENCY VIRUS-1 P24 PROTEIN", JOURNAL OF BIOCHEMISTRY AND MOLECULAR BIOLOGY, vol. 33, no. 1, 31 January 2000 (2000-01-31), pages 92 - 95, XP009040726, ISSN: 1225-8687 *

Also Published As

Publication number Publication date
WO2006027468A2 (fr) 2006-03-16
WO2006027468A3 (fr) 2006-06-29

Similar Documents

Publication Publication Date Title
Sulkowski et al. Boceprevir plus peginterferon/ribavirin for the treatment of HCV/HIV co-infected patients
CY1108299T1 (el) Πεπτιδια του ιου ανθρωπινης ανοσοανεπαρκειας (hiv), αντιγονα και συνθεσεις εμβολιου
SG155206A1 (en) Vaccine for prevention and treatment of hiv-infection
HK1068918A1 (en) A soluble complex comprising a retroviral surface glycoprotein
ATE455791T1 (de) T-cd4+-epitope der latenzantigene typ i und ii des epstein-barr-virus, die bei der mehrzahl von individuen in der kaukasischen bevölkerung erkannt werden können, und anwendungen davon
WO2002020554A3 (fr) Peptides vih, antigenes, compositions de vaccin, coffret de dosage immunologique et procede permettant la detection d'anticorps induits par vih
EA200200724A1 (ru) Вакцина для профилактической или терапевтической иммунизации против вируса иммунодефицита человека (вич)
ATE362379T1 (de) Induktion rev- und tat-spezifischer zytotoxischer t-zellen zur prävention und behandlung einer infektion durch humanen immundefizienz-virus (hiv)
BR0211296A (pt) Peptìdeo imunogênico derivado da proteìna g do vrs do sub-grupo a ou b, sequência de ácido nucleico, composição farmacêutica, anticorpos policlonais ou monoclonais, kit de diagnóstico, utilização de um peptìdeo imunogênico, e, conjugado
HUP0202502A2 (hu) Virális fertőzőképességet blokkoló peptidek és eljárások ezek alkalmazására
BR0108210A (pt) Vacina contra o vìrus da imunodeficiência humana
ATE306938T1 (de) Verwendung von cpg als adjuvans für hivimpstoff
FR2647810B1 (fr) Amorces oligonucleotidiques pour l'amplification du genome des retrovirus du type hiv-2 et siv, et leurs applications au diagnostic in vitro des infections dues a ces virus
NO20014841D0 (no) Anti-HIV-1 vaksine som omfatter hele eller del av HIV-1 TAT proteinet
FR2874612A1 (fr) Epitotes t cd4+ du vih restreints a hla-dp4 et leurs applications
DE69736474D1 (de) Antikörper gegen einen komplex aus cd4 und einer chemokinrezeptordomäne, sowie deren verwendung gegen hiv infektionen
HUP0303132A2 (hu) Szabályozó és kiegészítő HIV-peptidek, antigének, vakcinakészítmények, immunológiai mérési reagenskészletek és HIV által indukált antitestek detektálására szolgáló eljárás
DK1417222T3 (da) Isolerede polypeptider baseret på den neutraliserende epitop af p17-proteinet fra HIV egnet til vacciner samt neutraliserende anti-p17-antistoffer, der specifikt genkender nævnte neutraliserende epitop
WO2007018550A3 (fr) Compositions et methodes pour detecter une infection par le vih-1/vih-2
JP2007516701A5 (fr)
WO2003029285A3 (fr) Identification de nouveaux epitopes cd8 des proteines du vih-1 presentant des proprietes therapeutiques et vaccinales contre les infection par le vih
EP1370697A4 (fr) Medicaments a base de peroxyredoxine pour le traitement d'infections par le vih-1, et leurs methodes d'utilisation
WO2004027066A3 (fr) Protéine recombinante chimérique et diagnostic in vitro du hiv
WO2004108886A3 (fr) Composes anti-vih-1 a base de sequences d'acides amines conserves partages par gp160 et la proteine humaine cd4
HUP0303423A2 (hu) HIV elleni természetes ellenanyag

Legal Events

Date Code Title Description
ST Notification of lapse

Effective date: 20080430